Effets Secondaires des Vaccins COVID-19 dans le District Sanitaire de Bangourain (Cameroun)

Auteurs-es

  • Kum Jerry Ngha 1. Bangourain District Health Service, West region, Cameroon; PhD student University of Calabar
  • Kenmegne Noumsi Elvira 1. Bangourain District Health Service, West region, Cameroon; PhD student University of Calabar
  • Fankep Dihewou Alphonse 2. Faculty of Medicine, University of Douala, Douala, Cameroon
  • Ketchaji Alice. 3. Department of family Medicine, Ministry of Public Health, Yaoundé, Cameroon.
  • Tambo Erenest 4. Faculte de Médicine, Université des Montagnes, Bangangte, Cameroun.

DOI :

https://doi.org/10.5281/hra.v2i3.5367

Mots-clés :

COVID 19, Vaccin, effets secondaires, Bangourain Health District

Résumé

ABSTRACT
Introduction. Little is documented on the frequency, severity, and factors associated with Covid 19 vaccine side effects post vaccination campaigns in Cameroon. The main objective of the study was to evaluate post COVID19 vaccination side effects of approved government anti-covid vaccines occurrence, frequency of and severity in Bangourain Health District, Cameroon. Methodology. A cross sectional study was conducted. The data collection was collected for 4weeks from the 15 May to 15 June, 2022. Our sample size was consecutive. We included in our study everybody who has received at least one dose of any of the Covid 19 vaccines be it Sinopharm, Johnson-Johnson or Astra-Zenecca and who accepted to take part in the study. Results. A total of 162 participants were enrolled in the study with mean age of 42.77. The frequency of occurrence of side effects to Covid-19 vaccine was 66.7% for the first dose, 50.5% for the second dose and 54.8% for the third dose, all vaccine types combined. The most common side effects reported were local pain (84.67%), itch at injection site (15.38%), fever (15.38%), fatigue (15.38%) and functional Impotence (15.38%) for Sinopharm; local pains (68.18%), stiffness of arms (36.36%), Fatigue (36.36%), Headache (31.82%), and fever (25.00%) for AstraZeneca and local pains (90.20%), fatigue (31.37%), Headache (25.49%), fever (19.61%) and Itch at injection site (15.69%) for Johnson and Johnson. Conclusion. Irrespective of the type and dose of vaccine, many participants developed side effects after administration of Covid-19 vaccine, most of which are similar to those reported by manufacturers with certain disparities observed in the frequency of occurrence.
RÉSUMÉ
Introduction. Il existe peu de données sur la fréquence, la gravité et les facteurs associés aux effets secondaires du vaccin Covid 19 après les campagnes de vaccination au Cameroun. L'objectif principal de l'étude était d'évaluer l'occurrence, la fréquence et la gravité des effets secondaires post-vaccination COVID19 des vaccins anti-covidiens approuvés par le gouvernement dans le district sanitaire de Bangourain, au Cameroun. Méthodologie. Une étude transversale a été menée. Les données ont été collectées pendant 4 semaines, du 15 mai au 15 juin 2022. La taille de notre échantillon était consécutive. Nous avons inclus dans notre étude toutes les personnes ayant reçu au moi ns une dose de l'un des vaccins Covid 19 que ce soit Sinopharm, Johnson-Johnson ou Astra-Zenecca et qui ont accepté de participer à l'étude. Résultats. Au total, 162 participants ont été recrutés pour l'étude, avec un âge moyen de 42,77 ans. La fréquence d'apparition des effets secondaires du vaccin Covid-19 était de 66,7 % pour la première dose, de 50,5 % pour la deuxième dose et de 54,8 % pour la troisième dose, tous types de vaccins confondus. Les effets secondaires les plus fréquents étaient les suivants : douleur locale (84,67%), démangeaison au point d'injection (15,38%), fièvre (15,38%), fatigue (15,38%) et impuissance fonctionnelle (15,38%) pour Sinopharm ; douleur locale (68,18%), raideur des bras (36. 36%), fatigue (36,36%), maux de tête (31,82%) et fièvre (25,00%) pour AstraZeneca et douleurs locales (90,20%), fatigue (31,37%), maux de tête (25,49%), fièvre (19,61%) et démangeaisons au point d'injection (15,69%) pour Johnson and Johnson. Conclusion. Indépendamment du type et de la dose de vaccin, de nombreux participants ont développé des effets secondaires après l'administration du vaccin Covid-19, dont la plupart sont similaires à ceux rapportés par les fabricants avec certaines disparités observées dans la fréquence d'occurrence.

Références

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242. doi:10.10 01/jama.2020.2648

WHO. COVID-19 Weekly Epidemiological Update. Edition 75, published 18 January 2022.

Cameroon: COVID-19 Emergency Situation Report No. 21,p1, published 20 January 2022.

Mahmoodullah A.,1 Wazhma M.D.,Mohammad A.A.,1 Barin B.,Abdullah A. Adverse Effects of the COVID-19 Vaccine Reported by Lecturers and Staff of Kabul University of Medical Sciences, Kabul, Afghanistan.Septembre 2021. Infection and Drug Resistance,Volume 14.

Al Khames Aga QA, Alkhaffaf WH, Hatem TH, et al. Safety of COVID‐19 vaccines. J Med Virol. 2021;93:6588‐6594. https://doi.org/10.1002/jmv.27214

Alexis L.B., Noah D.P., Xochitl E.B, Jennifer M.C, Feng L,Jeffrey E.O, et al. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination.JAMA Network Open. 2021;4(12):e2140364

Johan W., Rivaldo S.H., Felix W., Devina A.H., Claudia C., Elizabeth M., et al. Factors associated with side effects of COVID-19 vaccine in Indonesia.Clin Exp Vaccine Res 2022;11:89-95.

Rivera-Izquierdo M., Soler-Iborte E., De Rojas J.P., Pegalajar-García M.D., Gil-Villalba A.; Ruiz-Villaverde R. et al. Factors Associated with Adverse Reactions to BNT162b2 COVID-19 Vaccine in a Cohort of 3969 Hospital Workers. Vaccines 2022, 10, 15. https:// doi.org/10.3390/vaccines10010015.

Téléchargements

Publié-e

2024-02-24

Comment citer

Kum Jerry Ngha, Kenmegne Noumsi Elvira, Fankep Dihewou Alphonse, Ketchaji Alice., & Tambo Erenest. (2024). Effets Secondaires des Vaccins COVID-19 dans le District Sanitaire de Bangourain (Cameroun). HEALTH RESEARCH IN AFRICA, 2(3). https://doi.org/10.5281/hra.v2i3.5367

Numéro

Vol. 2 No. 3 (2024): Health Research in Africa

Rubrique

Articles Originaux

Licence

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License  CC BY-NC-ND 4.0  that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

 

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

 

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work